BIOMAT Database Logo BIOMAT Database Logo

[Cellular immunity in patients with generalized myasthenia gravis]. 1986

M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
[Cellular immunity in myasthenia gravis].
December 1978, Revista do Hospital das Clinicas,
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Development of generalized myasthenia gravis in patients with ocular myasthenia gravis.
October 2003, Archives of neurology,
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Cellular changes in eculizumab early responders with generalized myasthenia gravis.
October 2021, Clinical immunology (Orlando, Fla.),
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Comment: Methotrexate for patients with generalized myasthenia gravis.
July 2016, Neurology,
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Comparison of clinical manifestations between patients with ocular myasthenia gravis and generalized myasthenia gravis.
February 2011, Korean journal of ophthalmology : KJO,
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Effect of thymectomy on cellular immunity in myasthenia gravis.
January 1978, Lancet (London, England),
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Hypereosinophilic syndrome with generalized myasthenia gravis.
March 1996, The Journal of pediatrics,
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Thymectomy in children with generalized myasthenia gravis.
October 1997, Neuropediatrics,
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Cellular immunity in myasthenia gravis after thymectomy and corticosteroid therapy.
January 1990, Japanese journal of medicine,
M I Kuzin, and L O Shkrob, and N V Chumachenko, and V A Golubkov, and I Kh Ippolitov
Humoral and cellular immunity to intrinsic factor in myasthenia gravis.
November 1979, Scandinavian journal of haematology,
Copied contents to your clipboard!